The first subject has been dosed in the phase 3 registrational COMET-3 study investigating AR-15512 for the treatment of dry eye disease, according to a press release from Aerie Pharmaceuticals.
AR-15512 is a differentiated, novel, first-in-class product candidate for the treatment of the signs and symptoms of Dry Eye DiseaseCOMET-3 is the second of three studies in the AR-15512 Registrational Phase 3 ProgramDURHAM, N.C. (BUSINESS WIRE) Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company.
01.08.2022 - Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that the first participant has been dosed in the Phase 3 . Seite 1
24.05.2022 - Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that the first participant has been dosed in the Phase 3 . Seite 1